Patent protects methods and devices for customized real time treatment of chronic inflammation related disorders with bioelectric stimulation based protein expressions and control.
📰 Read official PR Newswire press release here.
Leonhardt Ventures LLC, a clinical stage innovation development and venture creation firm, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,110,274 titled “System and Method of Treating Inflammation.” Click here for the published patent.
"We believe this to be the first patented device and method for precise customization of inflammation treatment. This is accomplished by first reading inflammation levels and then adjusting precise bioelectric signaling sequences to control specific anti-inflammatory cytokine expressions - at just the right time in the healing cycle," states Howard J. Leonhardt, Inventor, Executive Chairman, and CEO of Leonhardt Ventures LLC. "In our scientific team's opinion, previous inflammation treatments that attempted to deliver one single molecule, cytokine, or signal in a standardized dose for all patients with varying levels of inflammation failed to modulate inflammation properly. We believe that personalizing treatment based on a patient's real-time inflammation level and then stimulating customized cytokine expressions at the proper timing is a better path will achieve the best outcomes."
The ’274 patent with 15 patent claims issued becomes the nineteenth patent or patent pending of the Leonhardt IP estate related to bioelectric and biologics based organ regeneration and recovery.
Claim 1 of 15 of '274 issued patent:
A device that determines a subject's level of inflammation following organ and/or tissue injury in the subject and then, in response to said determination, is programmed to provide at least one bioelectric signal to tissue of the subject so as to regulate expression of selected protein(s) by the tissue, so as to balance inflammation in the subject for organ and/or tissue healing and recovery in the subject, wherein the device comprises: wherein the applied bioelectric signal(s) influence expression of protein(s) in the tissue of the subject to which a bioelectric signal or signals is applied.
Sensor(s) for determining the subject's level of inflammation; a microprocessor that, based upon the subject's level of inflammation, is programmed to provide at least one bioelectric signal in order to balance inflammation in the subject; and electrode(s) for applying bioelectric signal(s) to tissue of the subject.
Chronic inflammatory related diseases are amongst the most significant causes of death in the world. Research is building that suggests chronic inflammation plays a significant role in almost all disease and illness, including diabetes, cardiovascular diseases, arthritis, and joint diseases, Chronic Obstructive Pulmonary Disease (COPD), allergies, asthma, kidney disease, obesity, cancer, depression, dementia, anxiety, COVID coronavirus, Parkinson's, Alzheimer's disease and autoimmune diseases of all types, including Crohn's disease, ulcerative colitis, and irritable bowel syndrome.
Chronic inflammation occurs when the inflammation response goes overboard when dealing with a small problem often as small as a minor cut, injury or burn.
“There is a significant unmet medical need to find new ways to treat chronic inflammation-related disease progression in patients whose inflammation is inadequately controlled with conventional biologic or drug therapies,” said Leslie Miller, MD, Chief Medical Officer of Leonhardt Ventures LLC and Leonhardt's Launchpads innovation accelerator. “Our team looks forward to gathering additional statistically significant supporting data for this therapeutic candidate in well designed studies forward. We in particular have great excitement about applying this technology to potentially helping severe heart failure patients to recover where we believe chronic inflammation is a major contributing factor."
Leonhardt's Launchpads the innovation and startup launch accelerator arm of Leonhardt Ventures LLC has a full portfolio of innovation assets that will likely employ this patented inflammation treatment technology platform. The business model of this innovation accelerator is to help accelerate the pathway of organ or purpose specific applications of Leonhardt core IP through first in human studies and then secure a strategic partner/acquirer to advance that organ specific application through to commercialization.
This newly issued inflammation modulation patent complements well our previous patent filing for bioelectric klotho modulation a highly potent inflammation modulating circulating protein.
Leonhardt's Launchpads sponsored lab and clinical studies have demonstrated an ability to increase circulating klotho from 150% to up to 5X via bioelectric stimulation of skeletal muscle or over and under the kidneys or both.
A Leonhardt Ventures LLC innovation development team is working on BodStim a wearable bioelectric body suit currently in early stage evaluation and study that is intended in the future to be a possible option for increasing circulating klotho levels, once proven to be safe and effective.
Another Leonhardt Ventures LLC startup unit KlothoBios recently launched the KlothoYears blood test kit for measuring circulating klotho levels and reporting how they stand in relation to similar aged peers working in collaboration with known experienced test assay suppliers and a qualified laboratory in San Diego.
This inflammation treatment device and method is in early stages of development and is not yet proven to be either safe or effective. Significant technological hurdles exist to perfect the device as originally intended as described in this issued patent especially accurate real time reads of inflammation. Our team is working to partner with other firms focusing on rapid analysis of inflammation to combine with our bioelectric protein expression technology platform that is more advanced in development.
About Leonhardt Ventures LLC: Since 1982 the Leonhardt team has worked on innovations in medtech. In the 1980's the team patented, developed and brought to market the PolyCath TM line of cardiovascular balloon catheters. In the 1990's StentValve one of the first percutaneous delivered heart valves and TALENT (Taheri-Leonhardt) aortic aneurysm stent grafts. Since 2000 the team has focused primarily on the convergence of bioelectrics and biologics for organ regeneration and healing. In 2001 Leonhardt led a team that competed the first non-surgical repair of a human heart with muscle stem cells in The Netherlands.
About University Lab Partners
University Lab Partners is a premier, nonprofit, wet lab and medtech incubator located in UCI Research Park in Irvine, CA. ULP is a professionally managed and equipped wet lab facility along with the benefits of peer-to-peer interactions among a life science-focused entrepreneurial community. ULP is a project of The Beall Family Foundation.
Download The Ultimate Guide to Wet Lab Incubators in Southern California, a handbook to assist life science start-ups through the entire decision-making process to find wet lab space.DOWNLOAD NOW